

Analysis of Serum 17-Hydroxyprogesterone, Androstenedione, and Cortisol by UPLC-MS/MS for Clinical Research

Heather A Brown,¹ Claudia Rossi,² and Lisa J Calton¹

¹Waters Corporation, Wilmslow, UK

²Department of Biomedical Science, G. d'Annunzio University Foundation, Pescara, Italy

APPLICATION BENEFITS

- Single liquid-liquid extraction (LLE), without derivatization
- Analytical sensitivity for 17-hydroxyprogesterone, from limited-volume samples
- Chromatographic resolution of isobaric steroid intermediates

WATERS SOLUTIONS

ACQUITY UPLC® System

ACQUITY UPLC HSS T3 UPLC Column

ACQUITY UPLC HSS T3

VanGuard™ Pre-column

Xevo® TQ MS

TruView™ Maximum Recovery Vials

MassLynx® Software

TargetLynx™ Application Manager

KEY WORDS

17-hydroxyprogesterone, androstenedione, cortisol, deoxycortisol, corticosterone, adrenal steroid, UPLC-MS/MS

INTRODUCTION

Measurement of 17-hydroxyprogesterone (17-OHP) by immunoassay is prone to analytical interference arising from cross-reactivity of reagent antibodies with structurally-related steroid metabolites. A method for the extraction and UPLC®-MS/MS analysis of serum 17-OHP and two additional adrenal steroids, androstenedione (A4) and cortisol, using the ACQUITY UPLC System with the Xevo TQ MS (Figure 1) is described.



Figure 1. ACQUITY UPLC with Xevo TQ MS.

EXPERIMENTAL

Calibrators and quality-control material (QC) were prepared in double charcoal-stripped serum over the stated measurement range. Samples, 50 μL and 20 μL , of internal standard ($[^2\text{H}_6]$ 17-OHP, $[^2\text{H}_7]$ A4, and $[^2\text{H}_4]$ cortisol) were extracted into 1 mL of methyl-tert-butyl-ether. The evaporated organic layer (800 μL) was reconstituted in 50 μL 45% (v/v) methanol (aq).

LC conditions

System:	ACQUITY UPLC	Gradient (binary system):	Initial conditions of 45% mobile phase B were increased linearly to 47% over 1 minute and then, over an additional minute, to 57%. Thereafter, mobile phase B was again increased, this time to 98% over 0.5 minutes. The composition was then maintained at 98% B for 0.5 minutes before reverting to 45% B followed by column re-equilibration for 1.5 minutes. The overall run time was 4.5 minutes.
Sample preparation vials:	TruView LCMS Certified Maximum Recovery Vial (p/n 186005662CV)		
Column:	ACQUITY UPLC HSS T3, 1.8 μm , 2.1 x 50 mm (p/n 186003538) with an ACQUITY HSS T3, VanGuard Pre-column, 1.8 μm , 2.5 x 5 mm (p/n 186003976)		
Column temp.:	60 °C		
Sample temp.:	8 °C		
Injection volume:	20 μL		
Flow rate:	600 $\mu\text{L}/\text{min}$		
Injection mode:	Partial loop, with needle overfill (PLNO); Load ahead feature enabled (5 min injection-to-injection)	MS conditions	
Mobile phase A:	2 mmol/L ammonium acetate, 0.1 % (v/v) formic acid (aq)	System:	Xevo TQ (0.7 FWHM on MS1 and 0.8 FWHM MS2)
Mobile phase B:	2 mmol/L ammonium acetate, 0.1 % (v/v) formic acid in methanol	Ionization mode:	Electrospray positive
		Capillary voltage:	0.7 kV
		Collision energy:	Analyte specific (see Table 1)
		Cone voltage:	Analyte specific (see Table 1)

Data management

MassLynx Software v4.1 with TargetLynx Application Manager

Analyte	Precursor ion (m/z)	Product ion (m/z)	Cone voltage	Collision energy	Dwell time (s)	MS function (time window, in min)
Androstenedione (quantifier)	287	97	30	20	0.02	
Androstenedione*	287	109	30	20	0.02	1 (2.35–3.50)
17-OHP (quantifier)	331	97	28	26	0.02	
17-OHP*	331	109	28	28	0.02	
Cortisol (quantifier)	363	121	26	23	0.20	
Cortisol*	363	97	26	30	0.20	2 (0.00–1.70)

Table 1. MS Parameters. Optimize precursor and product ions to 1 decimal place.

*Denotes optional, qualifier ion transition. MS function-time windows were optimized for the instrument's duty cycle. Verify chromatogram-peak retention time using a single-function MS method before establishing time-window settings for routine use.

RESULTS AND DISCUSSION

The limit of detection (LOD) and lower limit of quantification (LLOQ) were determined as the lowest concentration of steroid spiked into charcoal-stripped serum to produce a signal-to-noise ratio (SNR) >3 or >8, respectively. The LLOQ was confirmed by demonstrating ≤15% imprecision and deviation from assigned values following replicate analysis (n = 10), a percentage value that surpasses the imprecision targets of ≤20% CV prescribed by the United States Food and Drug Administration (USFDA) in its Guidance for Industry.¹ The LOD and LLOQ were 0.25 and 0.5 ng/mL, respectively, for all analytes. Mass (ng/mL) to nanomolar-unit conversion factors are x3.03 for 17-OHP, x2.76 for cortisol, and x3.49 for A4.

The correlation between analyte concentration and response ratio was linear from the LLOQ to 300, 500, and 200 ng/mL for 17-OHP, cortisol, and A4, respectively. The coefficient of determination (r^2) for all analytes was >0.997. Figure 2 shows a calibration curve for 17-OHP. Calculated concentrations of calibrators were ≤10% of assigned values, with the exception of the lowest concentration calibrator at the LLOQ, for which a deviation of ≤15% from the nominal value was accepted.




Figure 2. Double charcoal-stripped serum calibration curve for 17-OHP.

The within-batch imprecision was determined from replicate ($n = 5$) analysis of multiple levels of QC. The maximum between-batch imprecision was evaluated by replicate ($n = 5$) analysis of the QC over five consecutive days. The findings are summarized in Table 2. The determined concentrations were $<7.5\%$ of nominal values.

Analyte	QC (ng/mL)	CV (W) %	CV (B) %
17-OHP	2.5	6.3	7.9
	25.0	3.5	9.0
	75.0	2.8	6.6
	250.0	3.4	4.4
Cortisol	2.5	2.8	5.9
	25.0	4.3	6.8
	75.0	2.3	1.4
	250.0	1.0	2.1
A4	2.5	4.9	2.3
	35	2.1	6.1
	75	3.5	2.5

Table 2. Within (W) and Between (B) batch imprecision determined from replicate analysis of QC. QC is categorized by nominal/weighed in concentration.

Recovery was evaluated as the ratio of detector response in pre- to post-extraction-spiked serum samples. Recovery was calculated as $>70\%$ for all steroids. The magnitude of electrospray ionization suppression from residual sample interferences was estimated by calculation of the matrix factor for each analyte. The matrix factor was defined as the mean ratio of the peak-area response in presence to absence of residual sample matrix ($n = 6$, human whole serum). These studies indicated approximately 10% of the detector signal for cortisol and A4, with 50% of the signal for 17-OHP was suppressed by residual matrix ions. The use of stable isotope-labeled internal standards compensated for the observed matrix effects.

Further interference studies were conducted whereby serum was supplemented with a selection of adrenal steroid intermediates, extracted and analyzed by the UPLC-MS/MS method described herein. A subset of intermediates, isobaric for the MRM transition $347 > 121$ were identified, namely: 11- and 21-deoxycortisol and corticosterone. Inspection of the total-ion chromatograms of the three isobars showed these steroids were resolved from one another (Figure 3). Interferences were not observed at or around the retention time of the compounds of interest in the $347 > 121$ total-ion chromatograms, confirming the analytical selectivity for the detection of 17-OHP, cortisol, and A4 with respect to the subset of steroid intermediates described herein.




Figure 3. Total-ion chromatogram of 11-deoxycortisol (11-DOC), corticosterone, and 21-deoxycortisol (21-DOC) in a 10 ng/mL aqueous standard. For reference, the retention times of cortisol, A4, and 17-OHP were 1.51, 2.57, and 2.70 minutes, respectively.

CONCLUSIONS

A rapid method for quantification of 17-OHP, cortisol, and A4 was developed using UPLC-MS/MS. Using MRM qualifier and quantifier ion transition ratios allows analytical sensitivity with added confidence in compound identity when clinical research requires a high level of analytical selectivity. The research method demonstrates good linearity, analytical sensitivity, and precision. The selectivity of the UPLC method enables chromatographic resolution of isobars for added confidence in the measured result.

References

1. Guidance for Industry for Bioanalytical Method Validation. (2001). U.S. Department of Health and Human Services, Food and Drug Administration.

For Research Use Only. Not for use in diagnostic procedures.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, Xevo, ACQUITY UPLC, MassLynx, and UPLC are registered trademarks of Waters Corporation. TruView, VanGuard, and TargetLynx are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com